Anne B Moser

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6772758/publications.pdf

Version: 2024-02-01

137 papers	12,019 citations	25014 57 h-index	29127 104 g-index
138 all docs	138 docs citations	138 times ranked	10763 citing authors

#	Article	IF	Citations
1	Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology, 2003, 37, 343-350.	3.6	800
2	Functions of plasmalogen lipids in health and disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 1442-1452.	1.8	768
3	Peroxisome biogenesis disorders. Biochimica Et Biophysica Acta - Molecular Cell Research, 2006, 1763, 1733-1748.	1.9	433
4	Mutations in the PTS1 receptor gene, PXR1, define complementation group 2 of the peroxisome biogenesis disorders. Nature Genetics, 1995, 9, 115-125.	9.4	432
5	Human PEX7 encodes the peroxisomal PTS2 receptor and is responsible for rhizomelic chondrodysplasia punctata. Nature Genetics, 1997, 15, 369-376.	9.4	415
6	Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Annals of Neurology, 1999, 45, 100-110.	2.8	321
7	Peroxisome biogenesis disorders in the Zellweger spectrum: An overview of current diagnosis, clinical manifestations, and treatment guidelines. Molecular Genetics and Metabolism, 2016, 117, 313-321.	0.5	314
8	Adrenoleukodystrophy: Incidence, new mutation rate, and results of extended family screening. Annals of Neurology, 2001, 49, 512-517.	2.8	294
9	Mutations in the gene encoding 3Î²-Âhydroxysteroid-Î”8,Î”7-Âisomerase cause X-linked dominant Conradi-HÃ¼nermann syndrome. Nature Genetics, 1999, 22, 291-294.	9.4	283
10	Phenotype of patients with peroxisomal disorders subdivided into sixteen complementation groups. Journal of Pediatrics, 1995, 127, 13-22.	0.9	249
11	Gene redundancy and pharmacological gene therapy: Implications for X-linked adrenoleukodystrophy. Nature Medicine, 1998, 4, 1261-1268.	15.2	237
12	The Inflammatory Myelinopathy of Adreno-Leukodystrophy. Journal of Neuropathology and Experimental Neurology, 1992, 51, 630-643.	0.9	228
13	Adrenoleukodystrophy: Elevated C26 fatty acid in cultured skin fibroblasts. Annals of Neurology, 1980, 7, 542-549.	2.8	214
14	Follow-up of 89 Asymptomatic Patients With Adrenoleukodystrophy Treated With Lorenzoâ€™s Oil. Archives of Neurology, 2005, 62, 1073.	4.9	205
15	Myelin Basic Protein as an Encephalitogen in Encephalomyelitis and Polyneuritis Following Rabies Vaccination. New England Journal of Medicine, 1987, 316, 369-374.	13.9	176
16	The Pex1-G844D mouse: A model for mild human Zellweger spectrum disorder. Molecular Genetics and Metabolism, 2014, 111, 522-532.	0.5	170
17	Adrenomyeloneuropathy. Journal of Neuropathology and Experimental Neurology, 2000, 59, 89-102.	0.9	168
18	Classical maple syrup urine disease and brain development: Principles of management and formula design. Molecular Genetics and Metabolism, 2010, 99, 333-345.	0.5	157

#	Article	IF	Citations
19	Newborn screening for X-linked adrenoleukodystrophy (X-ALD): Validation of a combined liquid chromatographyâ€“tandem mass spectrometric (LCâ€“MS/MS) method. Molecular Genetics and Metabolism, 2009, 97, 212-220.	0.5	154
20	Biochemical abnormalities in rhizomelic chondrodysplasia punctata. Journal of Pediatrics, 1988, 112, 726-733.	0.9	133
21	Abnormal sterol metabolism in patients with Conradi-Hï¿½nermann-Happle syndrome and sporadic lethal chondrodysplasia punctata. , 1999, 83, 213-219.		133
22	Dyslipidemia and Atherosclerosis Induced by Chronic Intermittent Hypoxia Are Attenuated by Deficiency of Stearoyl Coenzyme A Desaturase. Circulation Research, 2008, 103, 1173-1180.	2.0	132
23	Hif-2Î± Promotes Degradation of Mammalian Peroxisomes by Selective Autophagy. Cell Metabolism, 2014, 20, 882-897.	7.2	131
24	Adrenoleukodystrophy: Impaired oxidation of long chain fatty acids in cultured skin fibroblasts and adrenal cortex. Biochemical and Biophysical Research Communications, 1981, 102, 1223-1229.	1.0	128
25	A new dietary therapy for adrenoleukodystrophy: Biochemical and preliminary clinical results in 36 patients. Annals of Neurology, 1987, 21, 240-249.	2.8	122
26	Mutation analysis ofPEX7 in 60 probands with rhizomelic chondrodysplasia punctata and functional correlations of genotype with phenotype. Human Mutation, 2002, 20, 284-297.	1.1	122
27	Clinical, biochemical, and mutational spectrum of peroxisomal acylâ€“coenzyme A oxidase deficiency. Human Mutation, 2007, 28, 904-912.	1.1	121
28	Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening. Journal of Pediatrics, 2005, 146, 528-532.	0.9	120
29	A novel bile acid biosynthesis defect due to a deficiency of peroxisomal ABCD3. Human Molecular Genetics, 2015, 24, 361-370.	1.4	115
30	Adreno-leukodystrophy: Oxidative Stress of Mice and Men. Journal of Neuropathology and Experimental Neurology, 2005, 64, 1067-1079.	0.9	113
31	Clinical Aspects of Adrenoleukodystrophy and Adrenomyeloneuropathy. Developmental Neuroscience, 1991, 13, 254-261.	1.0	111
32	Xâ€linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies. International Journal of Developmental Neuroscience, 2020, 80, 52-72.	0.7	108
33	Potential Environmental and Host Participants in the Early White Matter Lesion of Adreno-Leukodystrophy: Morphologic Evidence for CD8 Cytotoxic T Cells, Cytolysis of Oligodendrocytes, and CD1-Mediated Lipid Antigen Presentation. Journal of Neuropathology and Experimental Neurology, 2001, 60, 1004-1019.	0.9	106
34	The PEX Gene Screen: molecular diagnosis of peroxisome biogenesis disorders in the Zellweger syndrome spectrum. Molecular Genetics and Metabolism, 2004, 83, 252-263.	0.5	106
35	Genetic and Phenotypic Heterogeneity in Disorders of Peroxisome Biogenesisâ€”A Complementation Study Involving Cell Lines from 19 Patients. Pediatric Research, 1989, 26, 67-72.	1.1	97
36	Combined liquid chromatographyâ€“Tandem mass spectrometry as an analytical method for high throughput screening for X-linked adrenoleukodystrophy and other peroxisomal disorders: Preliminary findings. Molecular Genetics and Metabolism, 2006, 89, 185-187.	0.5	97

#	Article	IF	Citations
37	The Prenatal Diagnosis of Adrenoleukodystrophy. Demonstration of Increased Hexacosanoic Acid Levels in Cultured Amniocytes and Fetal Adrenal Gland. Pediatric Research, 1982, 16, 172-175.	1.1	94
38	High concentration of hexacosanoate in cultured skin fibroblast lipids from adrenoleukodystrophy patients. Biochemical and Biophysical Research Communications, 1978, 82, 114-120.	1.0	92
39	Distinction between peroxisomal bifunctional enzyme and acyl-CoA oxidase deficiencies. Annals of Neurology, 1995, 38, 472-477.	2.8	88
40	Peroxisomal Straight-chain Acyl-CoA Oxidase and D-bifunctional Protein Are Essential for the Retroconversion Step in Docosahexaenoic Acid Synthesis. Journal of Biological Chemistry, 2001, 276, 38115-38120.	1.6	87
41	Phospholipids in X-linked adrenoleukodystrophy white matter: fatty acid abnormalities before the onset of demyelination. Journal of the Neurological Sciences, 1992, 110, 195-204.	0.3	86
42	A very long-chain acyl-CoA synthetase-deficient mouse and its relevance to X-linked adrenoleukodystrophy. Human Molecular Genetics, 2003, 12, 1145-1154.	1.4	82
43	The peroxisomal AAA ATPase complex prevents pexophagy and development of peroxisome biogenesis disorders. Autophagy, 2017, 13, 868-884.	4.3	81
44	Plasma and red blood cell fatty acids in peroxisomal disorders. Neurochemical Research, 1999, 24, 187-197.	1.6	80
45	Safety, efficacy and physiological actions of a lysine-free, arginine-rich formula to treat glutaryl-CoA dehydrogenase deficiency: Focus on cerebral amino acid influx. Molecular Genetics and Metabolism, 2011, 104, 93-106.	0.5	79
46	The Dorsal Root Ganglia in Adrenomyeloneuropathy: Neuronal Atrophy and Abnormal Mitochondria. Journal of Neuropathology and Experimental Neurology, 2001, 60, 493-501.	0.9	77
47	Contiguous Deletion of the X-Linked Adrenoleukodystrophy Gene (ABCD1) and DXS1357E: A Novel Neonatal Phenotype Similar to Peroxisomal Biogenesis Disorders. American Journal of Human Genetics, 2002, 70, 1520-1531.	2.6	76
48	Homeostasis of phospholipids â€" The level of phosphatidylethanolamine tightly adapts to changes in ethanolamine plasmalogens. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 117-128.	1.2	76
49	Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy. Human Molecular Genetics, 2005, 14, 1293-1303.	1.4	74
50	Newborn Screening for X-Linked Adrenoleukodystrophy. International Journal of Neonatal Screening, 2016, 2, 15.	1.2	72
51	Mutations in Novel Peroxin Gene PEX26 That Cause Peroxisome-Biogenesis Disorders of Complementation Group 8 Provide a Genotype-Phenotype Correlation. American Journal of Human Genetics, 2003, 73, 233-246.	2.6	71
52	â€œLorenzoâ€™s Oilâ€•Therapy for X-linked Adrenoleukodystrophy: Rationale and Current Assessment of Efficacy. Journal of Molecular Neuroscience, 2007, 33, 105-113.	1.1	71
53	Loss- or Gain-of-Function Mutations in ACOX1 Cause Axonal Loss via Different Mechanisms. Neuron, 2020, 106, 589-606.e6.	3.8	71
54	First trimester prenatal diagnosis of adrenoleukodystrophy by determination of very long chain fatty acid levels and by linkage analysis to a DNA probe. Human Genetics, 1985, 69, 272-274.	1.8	63

#	Article	IF	Citations
55	Mff functions with Pex11pÎ² and DLP1 in peroxisomal fission. Biology Open, 2013, 2, 998-1006.	0.6	63
56	Functional characterization of novel mutations in GNPAT and AGPS, causing rhizomelic chondrodysplasia punctata (RCDP) types 2 and 3. Human Mutation, 2012, 33, 189-197.	1.1	62
57	Chronic elevation of phosphocholine containing lipids in mice exposed to Gulf War agents pyridostigmine bromide and permethrin. Neurotoxicology and Teratology, 2013, 40, 74-84.	1.2	62
58	Brain endothelial dysfunction in cerebral adrenoleukodystrophy. Brain, 2015, 138, 3206-3220.	3.7	61
59	Role of lysosomal acid ceramidase in the metabolism of ceramide in human skin fibroblasts. Archives of Biochemistry and Biophysics, 1981, 208, 444-455.	1.4	60
60	Brain, liver, and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo's Oil). Neurochemical Research, 1994, 19, 1073-1082.	1.6	60
61	A Pex7 hypomorphic mouse model for plasmalogen deficiency affecting the lens and skeleton. Molecular Genetics and Metabolism, 2010, 99, 408-416.	0.5	59
62	Identification of novel mutations and sequence variation in the Zellweger syndrome spectrum of peroxisome biogenesis disorders. Human Mutation, 2009, 30, E467-E480.	1.1	58
63	Phenotypic variability in siblings with Farber disease. Journal of Pediatrics, 1984, 104, 406-409.	0.9	56
64	Solvent Vapor Abuse Leukoencephalopathy. Comparison to Adrenoleukodystrophy. Journal of Neuropathology and Experimental Neurology, 1994, 53, 389-398.	0.9	56
65	Neurodegenerative course in ceramidase deficiency (Farber disease) correlates with the residual lysosomal ceramide turnover in cultured living patient cells. Journal of the Neurological Sciences, 1995, 134, 108-114.	0.3	56
66	The Peroxisome Deficient PEX2 Zellweger Mouse: Pathologic and Biochemical Correlates of Lipid Dysfunction. Journal of Molecular Neuroscience, 2001, 16, 289-298.	1.1	55
67	Streamlined determination of lysophosphatidylcholines in dried blood spots for newborn screening of X-linked adrenoleukodystrophy. Molecular Genetics and Metabolism, 2015, 114, 46-50.	0.5	54
68	Mutations in PCYT1A, Encoding a Key Regulator of Phosphatidylcholine Metabolism, Cause Spondylometaphyseal Dysplasia with Cone-Rod Dystrophy. American Journal of Human Genetics, 2014, 94, 105-112.	2.6	53
69	Docosahexaenoic acid mediates peroxisomal elongation, a prerequisite for peroxisome division. Journal of Cell Science, 2012, 125, 589-602.	1.2	51
70	Newborn screening for X-linked adrenoleukodystrophy: Further evidence high throughput screening is feasible. Molecular Genetics and Metabolism, 2014, 111, 55-57.	0.5	51
71	Adenoassociated Virus Serotype 9-Mediated Gene Therapy for X-Linked Adrenoleukodystrophy. Molecular Therapy, 2015, 23, 824-834.	3.7	51
72	Peroxisome assembly mutations in humans: Structural heterogeneity in Zellweger syndrome. Journal of Cellular Physiology, 1992, 151, 103-112.	2.0	50

#	Article	IF	Citations
73	Neuronal migration abnormality in peroxisomal bifunctional enzyme defect. Annals of Neurology, 1996, 39, 268-271.	2.8	50
74	Myelin Membrane from Adrenoleukodystrophy Brain White Matter?Biochemical Properties. Journal of Neurochemistry, 1983, 41, 341-348.	2.1	49
75	Alterations in the Plasma Levels of Specific Choline Phospholipids in Alzheimerâ€™s Disease Mimic Accelerated Aging. Journal of Alzheimer's Disease, 2018, 62, 841-854.	1.2	48
76	Structural and Chemical Alterations in the Cerebral Maldevelopment of Fetal Cerebro-Hepato-Renal (Zellweger) Syndrome. Journal of Neuropathology and Experimental Neurology, 1989, 48, 270-289.	0.9	47
77	X-linked adrenoleukodystrophy: ABCD1 de novo mutations and mosaicism. Molecular Genetics and Metabolism, 2011, 104, 160-166.	0.5	46
78	Neonatal detection of Aicardi GoutiÃ¨res Syndrome by increased C26:0 lysophosphatidylcholine and interferon signature on newborn screening blood spots. Molecular Genetics and Metabolism, 2017, 122, 134-139.	0.5	43
79	Allelic Expression Imbalance Promoting a Mutant PEX6 Allele Causes Zellweger Spectrum Disorder. American Journal of Human Genetics, 2017, 101, 965-976.	2.6	41
80	Increased very long chain fatty acids in patients on a ketogenic diet: A cause of diagnostic confusion. Journal of Pediatrics, 1993, 122, 724-726.	0.9	40
81	Peroxisomal Disorders: Overview. Annals of the New York Academy of Sciences, 1996, 804, 427-441.	1.8	40
82	PEX7 Gene Structure, Alternative Transcripts, and Evidence for a Founder Haplotype for the Frequent RCDP Allele, L292ter. Genomics, 2000, 63, 181-192.	1.3	40
83	A metabolomic map of Zellweger spectrum disorders reveals novel disease biomarkers. Genetics in Medicine, 2018, 20, 1274-1283.	1.1	40
84	The role of peroxisomal ABC transporters in the mouse adrenal gland: the loss of Abcd2 (ALDR), Not Abcd1 (ALD), causes oxidative damage. Laboratory Investigation, 2007, 87, 261-272.	1.7	39
85	<scp>MRI</scp> surveillance of boys with Xâ€linked adrenoleukodystrophy identified by newborn screening: Metaâ€analysis and consensus guidelines. Journal of Inherited Metabolic Disease, 2021, 44, 728-739.	1.7	39
86	Early manifestations of multiple sulfatase deficiency. Journal of Pediatrics, 1984, 104, 574-578.	0.9	38
87	Peroxisomal Disease Cell Lines with Cellular Plasmalogen Deficiency Have Impaired Muscarinic Cholinergic Signal Transduction Activity and Amyloid Precursor Protein Secretion. Biochemical and Biophysical Research Communications, 1998, 248, 57-61.	1.0	37
88	Î±â€Synuclein abnormalities in mouse models of peroxisome biogenesis disorders. Journal of Neuroscience Research, 2010, 88, 866-876.	1.3	36
89	Human Acid Ceramidase Gene: Novel Mutations in Farber Disease. Molecular Genetics and Metabolism, 2000, 70, 301-309.	0.5	34
90	Cognitive Evaluation of Neurologically Asymptomatic Boys With X-linked Adrenoleukodystrophy. Archives of Neurology, 2006, 63, 69.	4.9	34

#	Article	IF	Citations
91	Mutations in the Peroxin Pex26p Responsible for Peroxisome Biogenesis Disorders of Complementation Group 8 Impair Its Stability, Peroxisomal Localization, and Interaction with the Pex1pÂ·Pex6p Complex. Journal of Biological Chemistry, 2006, 281, 1317-1323.	1.6	33
92	The prenatal diagnosis of X-linked adrenoleukodystrophy. , 1999, 19, 46-48.		32
93	Newborn Screening for Adrenoleukodystrophy. Molecular Diagnosis and Therapy, 2007, 11, 381-384.	1.6	32
94	Combined extraction of acyl carnitines and 26:0 lysophosphatidylcholine from dried blood spots: Prospective newborn screening for X-linked adrenoleukodystrophy. Molecular Genetics and Metabolism, 2012, 105, 416-420.	0.5	32
95	Anti-ganglioside antibodies bind with enhanced affinity to gangliosides containing very long chain fatty acids. Neurochemical Research, 2002, 27, 847-855.	1.6	31
96	Peroxisomal biogenesis is genetically and biochemically linked to carbohydrate metabolism in Drosophila and mouse. PLoS Genetics, 2017, 13, e1006825.	1.5	31
97	Biomarker Identification, Safety, and Efficacy of High-Dose Antioxidants for Adrenomyeloneuropathy: a Phase II Pilot Study. Neurotherapeutics, 2019, 16, 1167-1182.	2.1	31
98	Very long-chain fatty acids in diagnosis, pathogenesis, and therapy of peroxisomal disorders. Lipids, 1996, 31, S141-S144.	0.7	30
99	Characterization and application of a disease-cell model for a neurodegenerative lysosomal disease. Molecular Genetics and Metabolism, 2014, 111, 172-183.	0.5	29
100	Diagnosis of a mild peroxisomal phenotype with next-generation sequencing. Molecular Genetics and Metabolism Reports, 2016, 9, 75-78.	0.4	29
101	Investigational Methods for Peroxisomal Disorders. Current Protocols in Human Genetics, 2008, 58, Unit 17.6.	3.5	28
102	Identification of differences in human and great ape phytanic acid metabolism that could influence gene expression profiles and physiological functions. BMC Physiology, 2010, 10, 19.	3.6	28
103	Cerebral X-linked adrenoleukodystrophy in a girl with Xq27-Ter deletion. Annals of Neurology, 2002, 52, 234-237.	2.8	26
104	Human and great ape red blood cells differ in plasmalogen levels and composition. Lipids in Health and Disease, 2011, 10, 101.	1.2	26
105	Bezafibrate for X-Linked Adrenoleukodystrophy. PLoS ONE, 2012, 7, e41013.	1.1	26
106	Newborn Screening and Emerging Therapies for X-Linked Adrenoleukodystrophy. JAMA Neurology, 2018, 75, 1175.	4.5	25
107	Effect of Erucic Acid on Platelets in Patients with Adrenoleukodystrophy. Biochemical and Molecular Medicine, 1996, 57, 125-133.	1.5	22
108	Peroxisomal Very Long Chain Fatty Acid Î²-Oxidation Activity Is Determined by the Level of Adrenodeukodystrophy Protein (ALDP) Expression. Molecular Genetics and Metabolism, 1999, 66, 91-99.	0.5	22

#	Article	IF	Citations
109	Therapeutic strategies in adrenoleukodystrophy. Wiener Medizinische Wochenschrift, 2017, 167, 219-226.	0.5	21
110	Antioxidant Capacity and Superoxide Dismutase Activity in Adrenoleukodystrophy. JAMA Neurology, 2017, 74, 519.	4.5	21
111	Zellweger Syndrome Amniocytes: Morphological Appearance and a Simple Sedimentation Method for Prenatal Diagnosis. Pediatric Research, 1988, 24, 63-67.	1.1	20
112	The peroxisomal fatty acid transporter ABCD1/PMP-4 is required in the C. elegans hypodermis for axonal maintenance: A worm model for adrenoleukodystrophy. Free Radical Biology and Medicine, 2020, 152, 797-809.	1.3	19
113	Biochemical Characterization of Myelin Isolated from the Central Nervous System of Xenopus Tadpoles. Journal of Neurochemistry, 1980, 34, 1241-1246.	2.1	17
114	Diagnosis and Follow-Up of a Case of Peroxisomal Disorder With Peroxisomal Mosaicism. Journal of Child Neurology, 1999, 14, 434-439.	0.7	17
115	Effects of hematopoietic stem cell transplantation on acylâ€CoA oxidase deficiency: a sibling comparison study. Journal of Inherited Metabolic Disease, 2014, 37, 791-799.	1.7	17
116	A Liver-Specific Defect of Acyl-CoA Degradation Produces Hyperammonemia, Hypoglycemia and a Distinct Hepatic Acyl-CoA Pattern. PLoS ONE, 2013, 8, e60581.	1.1	16
117	A homozygous mutation in PEX16 identified by whole-exome sequencing ending a diagnostic odyssey. Molecular Genetics and Metabolism Reports, 2015, 5, 15-18.	0.4	16
118	Peroxisomal ghosts are intracellular structures distinct from lysosomal compartments in Zellweger Syndrome: A confocal laser scanning microscopy study. Biology of the Cell, 2000, 92, 85-94.	0.7	15
119	Neonatal adrenoleukodystrophy presenting as infantile progressive spinal muscular atrophy. Pediatric Neurology, 1993, 9, 496-497.	1.0	14
120	Induced pluripotent stem cell models of Zellweger spectrum disorder show impaired peroxisome assembly and cell type-specific lipid abnormalities. Stem Cell Research and Therapy, 2015, 6, 158.	2.4	12
121	Dietary influences on tissue concentrations of phytanic acid and AMACR expression in the benign human prostate. Prostate, 2015, 75, 200-210.	1.2	12
122	Nervonic Acid Attenuates Accumulation of Very Long-Chain Fatty Acids and is a Potential Therapy for Adrenoleukodystrophy. Neurotherapeutics, 2022, 19, 1007-1017.	2.1	12
123	A modelâ€based approach to assess the exposureâ€“response relationship of Lorenzo's oil in adrenoleukodystrophy. British Journal of Clinical Pharmacology, 2016, 81, 1058-1066.	1.1	11
124	Serum phytanic and pristanic acid levels and prostate cancer risk in Finnish smokers. Cancer Medicine, 2014, 3, 1562-1569.	1.3	10
125	Analysis of Peroxisomes in Lymphoblasts: Zellweger Syndrome and a Patient with a Deletion in Chromosome 7. Pediatric Research, 1993, 33, 441-444.	1.1	7
126	Red Blood Cell Fatty Acid Analysis for Determining Compliance with Omega3 Supplements in Dry Eye Disease Trials. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 837-841.	0.6	7

#	Article	IF	Citations
127	Familial risk for bipolar disorder is not associated with impaired peroxisomal function: Dissociation from docosahexaenoic acid deficits. Psychiatry Research, 2016, 246, 803-807.	1.7	7
128	X-linked Adrenoleukodystrophy: Pathology, Pathophysiology, Diagnostic Testing, Newborn Screening, and Therapies. International Journal of Developmental Neuroscience, 2019, , .	0.7	7
129	Newborn Screening for X-Linked Adrenoleukodystrophy: Past, Present, and Future. International Journal of Neonatal Screening, 2022, 8, 16.	1.2	6
130	Diverse captive non-human primates with phytanic acid-deficient diets rich in plant products have substantial phytanic acid levels in their red blood cells. Lipids in Health and Disease, 2013, 12, 10.	1.2	5
131	Drug discovery for Xâ€linked adrenoleukodystrophy: An unbiased screen for compounds that lower very longâ€chain fatty acids. Journal of Cellular Biochemistry, 2021, 122, 1337-1349.	1.2	5
132	X-linked adrenoleukodystrophy in a chimpanzee due to an ABCD1 mutation reported in multiple unrelated humans. Molecular Genetics and Metabolism, 2017, 122, 130-133.	0.5	5
133	Altered phospholipid molecular species and glycolipid composition in brain, liver and fibroblasts of Zellweger syndrome. Neuroscience Letters, 2013, 552, 71-75.	1.0	4
134	Serendipitous effects of Î²-cyclodextrin on murine model of Krabbe disease. Molecular Genetics and Metabolism Reports, 2018, 15, 98-99.	0.4	4
135	Effects of subperineurial injections of very-long-chain and medium-chain fatty acids into rat sciatic nerve. Neurochemical Pathology, 1986, 5, 71-83.	1.1	3
136	Associations Between Systemic Omega-3 Fatty Acid Levels With Moderate-to-Severe Dry Eye Disease Signs and Symptoms at Baseline in the Dry Eye Assessment and Management Study. Eye and Contact Lens, 2021, 47, 2-7.	0.8	3
137	Dataset for a case report of a homozygous PEX16 F332del mutation. Data in Brief, 2016, 6, 722-727.	0.5	1